



GlaxoSmithKline
Supplier Diversity
5 Moore Drive
PO Box 13398
Durham, NC 27709-3398
Tel. 919.315.3781
Fax: 336.369.8974
www.gsk.com

VIA ELECTRONIC MAIL (AGO.highcostprescriptiondrugs@vermont.gov)

September 23, 2020

Office of The Attorney General
State of Vermont
Attn: TJ Donovan, Attorney General
109 State Street
Montpelier, VT 05609

RE: Notice of New Prescription Drug Pursuant to 18 V.S.A §4637(b)

Dear Mr. Donovan:

On August 24, 2019, GlaxoSmithKline ("GSK") issued a notice pursuant to 18 V.S.A §4637(b) to inform you that on August 21, 2020 GSK introduced a new prescription drug to market (in the U.S. and Vermont) at a wholesale acquisition price above the threshold set for a specialty drug under the Medicare Part D program.

The new drug, listed below with its respective NDC, is:

- (1) BLENREP, BLENREP INJ 100 MG (NDC: 00173089601)

This letter is to provide reporting requirements under 18 V.S.A §4637 (c).

Reporting Requirement Under 18 V.S.A §4637(c)	Reporting Requirement Response for BLENREP (NDC: 00173089601)
(1) a description of the marketing and pricing plans used in the launch of the new drug in the United States and internationally	GSK has not made marketing and pricing plans available in the public domain and is limiting its response to information that which is otherwise in the public domain or publicly available under 18 V.S.A §4637(d)
(2) the estimated volume of patients who may be prescribed the drug	There is no specific information regarding the estimated volume of patients who may be prescribed BLENREP (NDC:00173089601) for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent available in the public domain. GSK is limiting its response to information that which is

	otherwise in the public domain or publicly available under 18 V.S.A §4637(d). Diagnosed patients may or may not be prescribed BLENREP (NDC:00173089601) depending on their known resistance to the medicines and other patient specific factors such as allergic reactions or other medical conditions that may preclude a patient's ability to be effectively treated with BLENREP (NDC:00173089601).
(3) whether the drug was granted breakthrough therapy designation or priority review by the FDA prior to final approval	BLENREP (NDC:00173089601) was granted breakthrough therapy designation and priority review by the FDA prior to final approval
(4) the date and price of acquisition if the drug was not developed by the manufacturer	BLENREP (NDC:00173089601) was developed by GSK

Kind Regards,

Jen Smith
Pricing Operations Manager
Payer Marketing
US

Email Jennifer.3.smith@gsk.com